pCN-ACO2-GFP
(Plasmid
#45330)
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 45330 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepBM16
- Total vector size (bp) 7694
-
Modifications to backboneSacI/Acc65I digest used to move ACO2pr-GFP-terminator fragment from pCU-ACO2-GFP to the pBM16 backbone. Note the ACO2 promoter naturally contains an Acc65I site, so a complete SacI/partial Acc65I digest was used to mobilize the fragment.
-
Vector typeC. glabrata expression
-
Selectable markersnourseothricin (NAT)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH10B
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameyeGFP
-
Alt nameGFP
-
SpeciesSynthetic
-
Insert Size (bp)717
- Promoter ACO2
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site EcoRI (unknown if destroyed)
- 3′ cloning site SalI (unknown if destroyed)
- 5′ sequencing primer M13F (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Please note that Addgene's sequencing results found a single nucleotide insertion between bp# 427 and 428 when compared to the full plasmid sequence. According to the depositing laboratory, this insertion has no effect on the function of the plasmid.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pCN-ACO2-GFP was a gift from Brendan Cormack (Addgene plasmid # 45330 ; http://n2t.net/addgene:45330 ; RRID:Addgene_45330) -
For your References section:
Expression plasmids for use in Candida glabrata. Zordan RE, Ren Y, Pan SJ, Rotondo G, De Las Penas A, Iluore J, Cormack BP. G3 (Bethesda). 2013 Oct 3;3(10):1675-86. doi: 10.1534/g3.113.006908. 10.1534/g3.113.006908 PubMed 23934995